Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Intrepid1 who wrote (1129)	6/12/1999 10:15:00 PM
From: Wisee	Read Replies (1) \| Respond to of 1185

An article in the Edmonton Journal on May 21/99 caught my attention: F. Hoffman LaRoche (Roche) a Swiss pharmaceutical company has pleaded guilty to price fixing of certain vitamins. They have been fined US$500 million and as a result Roche also faces a number of civil class action lawsuits in the US which could be in the hundred of million dollars. Also Roche's upper level management have been replaced with new management in the past month. I am wondering if any of the above may have contributed to the withdrawal of the agreement by Roche. Be your own judge!! I also understand Nortran's molecules that Roche were experimenting with were very satisfactory. Remember the fundamentals for Nortran remain intact. This is only a temporary setback. Continuing along, Wisee

To: Intrepid1 who wrote (1129)	6/14/1999 5:56:00 PM
From: Saracen	Respond to of 1185

This posting brings up an interesting point: If NRT has a significant number of US shareholders, do not be surprised if we see a class-action lawsuit thrown NRT's way - there may be many "ambulance-chasing" lawyers out there who would love to get their hands on NRT's cash horde. Even without a class-action lawsuit, I think that NRT's stock will under-perform for many months to come, regardless of what new partners they bring in, and this is because the company has blown any credibility that it had - management was telling everyone that the Hoffman LaRoche deal was basically done, when obviously it was not.